

Patent Docket P0960R1D1C2

REMARKS

Claims 35-37 and 39-42 are pending and are the subject of the present Office Action. For the Examiner's convenience, a clean copy of pending claims 35-37 and 39-42 are provided above.

In the Office Action, the pending claims were rejected under Section 112, first paragraph, as containing subject matter not sufficiently described to convey possession of the claimed invention. Applicants respectfully traverse the rejection.

As disclosed in the specification, the I-TRAF molecules can be used as therapeutics for the treatment of pathological conditions associated with downstream effects of the oncogene LMP1 on cell growth and gene expression (e.g., specification at page 32, lines 16-25). LMP1 is an Epstein-Barr virus transforming protein. On pages 39-40, Applicants describe the experimentally determined ability of I-TRAF to inhibit the activation of NF- κ B. Based on their ability to block TRAF-mediated signaling through LMP1, the I-TRAFs of the present invention may inhibit the downstream effects of LMP1, including LMP1-mediated NF- κ B activation (specification at page 32, lines 22-25). Methods or techniques for employing the I-TRAF molecules are described on pages 33-35 of the specification, including therapeutically acceptable carriers, routes of administration, and dosage ranges. Accordingly, it is believed that the claimed methods are fully and clearly described in the specification in a way that demonstrates possession of these claimed embodiments. Withdrawal of the rejection is therefore respectfully requested.

Respectfully submitted,
GENENTECH, INC.

Date: April 10, 2002

By: Diane L. Marschang
Diane L. Marschang
Reg. No. 35,600

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881